Sugi Predict

Sugi Predict / Compounds / SCHEMBL907049

SCHEMBL907049

SCHEMBL907049

Cn1cc2cc(B3OC(C)(C)C(C)(C)O3)ccc2n1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.40
▸ LPL P06858 11/20 0.40
▸ LIPG Q9Y5X9 11/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ TDO2 P48775 1/20 0.39
▸ SNCA P37840 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ NSD2 O96028 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ EGFR P00533 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31387338 0.90 IRAK4 (0.39) KDM4ELPLLIPGIDO1TDO2
SCHEMBL5137400 0.88 MAPT (0.49) KDM4ELPLLIPGIDO1TDO2
SCHEMBL31394882 0.82 LPL (0.43) LPLLIPGIDO1TDO2SNCA
SCHEMBL17113535 0.81 IRAK4 (0.39) LPLLIPGIDO1TDO2SNCA
SCHEMBL17113584 0.81 LPL (0.41) LPLLIPGIDO1TDO2SNCA
SCHEMBL23638441 0.81 FFAR1 (0.39) LPLLIPGIDO1TDO2SNCA
SCHEMBL31752127 0.80 IDO1 (0.39) LPLLIPGIDO1TDO2SNCA
SCHEMBL30928610 0.80 IDO1 (0.39) LPLLIPGIDO1TDO2SNCA
SCHEMBL31467299 0.79 ESR2 (0.40) LPLLIPGIDO1TDO2SNCA
SCHEMBL23546464 0.79 LPL (0.35) LPLLIPGIDO1TDO2SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695405-A2 SMALL-MOLECULE REGULATED ALTERNATIVE SPLICING Rgenta Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 — — US disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 — — US disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2025-05-01 — — US disclosed
EP-4504709-A1 CDK9 INHIBITORS Biolexis Therapeutics, Inc. (US) 2025-02-12 — — EP disclosed
CN-114728980-B Pyrazole compounds 江苏先声药业有限公司 2025-02-07 — — CN disclosed
US-20250042879-A1 HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-02-06 — — US disclosed
WO-2025016391-A1 THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF 南京再明医药有限公司 2025-01-23 — — WO disclosed
WO-2013148603-A1 CINNOLINE DERIVATIVES AS AS BTK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-03 — — WO disclosed
WO-2013063549-A1 SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2013-05-02 — — WO disclosed
WO-2013063549-A1 SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2013-05-02 — — WO disclosed
EP-2276759-B1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES LILLY CO ELI (US) 2011-10-19 — — EP disclosed
US-20110183988-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2011-07-28 — — US disclosed
US-20110183988-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2011-07-28 — — US disclosed
US-7932274-B2 3-indazolyl-4-pyridylisothiazoles ELI LILLY AND COMPANY (US) 2011-04-26 — — US disclosed
EP-2276759-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES Eli Lilly & Company (US) 2011-01-26 — — EP disclosed
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY 2009-10-08 — — US disclosed
WO-2009123855-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY (US) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B KDM4E 43/4885LPL 2804/4885LIPG 2297/4885
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES CYP3A4, IPO4, JAK3 KDM4E 963/4885LPL 3124/4885LIPG 4624/4885
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB KDM4E 1884/4885LPL 2558/4885LIPG 1174/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A KDM4E 444/4885LPL 2188/4885LIPG 2472/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN KDM4E 1882/4885LPL 3972/4885LIPG 3859/4885
US-20250042879-A1 HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME RBM17, SF3B5, SF3A2 KDM4E 3107/4885LPL 2502/4885LIPG 2815/4885
US-20110183988-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, ARAF, NRAS KDM4E 3625/4885LPL 3310/4885LIPG 1039/4885
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 KDM4E 3046/4885LPL 1855/4885LIPG 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.